The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 49 results:
Author Title Type [ Year(Asc)]
Filters: Author is Makras, Polyzois  [Clear All Filters]
2023
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Anastasilakis, A. D., Makras P., Polyzos S. A., & Papapoulos S. E. (2023).  The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.. Calcif Tissue Int.
Anastasilakis, A. D., Polyzos S. A., Vorkas P. A., Gkiomisi A., Yavropoulou M. P., Rauner M., et al. (2023).  Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study.. J Clin Med. 12(16), 
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
2022
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Anastasilakis, A. D., Papachatzopoulos S., Makras P., Gkiomisi A., Nikolakopoulos P., Polyzos S. A., et al. (2022).  The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. Bone. 158, 116354.
2021
Yavropoulou, M. P., Kolynou A., Makras P., Pikilidou M., Nanoudis S., Skoura L., et al. (2021).  Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss.. Biomedicines. 9(4), 
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Anastasilakis, A. D., Polyzos S. A., Makras P., Trovas G., Yavropoulou M. P., & Tournis S. (2021).  Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.. J Clin Densitom.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Anastasilakis, A. D., Polyzos S. A., Kitridis D., Makras P., Yavropoulou M. P., Palermo A., et al. (2021).  Ιrisin levels in postmenopausal women with an incident hip fracture.. Endocrine. 73(3), 719-722.
2020
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., & Makras P. (2020).  Combination and sequential treatment in women with postmenopausal osteoporosis.. Expert Opin Pharmacother. 21(4), 477-490.
Makras, P., Babis G. C., Chronopoulos E., Karachalios T., Kazakos K., Paridis D., et al. (2020).  Experience gained from the implementation of the fracture liaison service in Greece.. Arch Osteoporos. 15(1), 12.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.
2019
Anastasilakis, D. A., Makras P., Polyzos S. A., & Anastasilakis A. D. (2019).  Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview.. Hormones (Athens). 18(1), 65-70.
Anastasilakis, A. D., Tsourdi E., Makras P., Polyzos S. A., Meier C., McCloskey E. V., et al. (2019).  Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.. Bone. 127, 401-418.
Anastasilakis, A. D., Polyzos S. A., Makras P., Rauner M., Sonnleitner L., Hawa G., et al. (2019).  Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.. J Musculoskelet Neuronal Interact. 19(3), 253-257.
Tsourdi, E., Makras P., Rachner T. D., Polyzos S., Rauner M., Mandanas S., et al. (2019).  Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.. Bone. 120, 44-49.
Anastasilakis, A. D., Polyzos S. A., Makras P., Douni E., & Mantzoros C. S. (2019).  Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism. 93, 100-102.
Polyzos, S. A., Makras P., Tournis S., & Anastasilakis A. D. (2019).  Off-label uses of denosumab in metabolic bone diseases.. Bone. 129, 115048.
Anastasilakis, A. D., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Makras P. (2019).  Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.. J Bone Miner Res.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.